CLPT ClearPoint Neuro (CLPT) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001285550
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
71
13F, latest reported quarter
Conversions, 180 days
11
Codes C/M, not in net · $248.4K priced
What the filings say about CLPT
Insiders, 180 days
-$1.8M net sold
4 sellers · 0% of sales under a 10b5-1 plan
ClearPoint Neuro insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ClearPoint Neuro, Inc. insiders sold a net $1.8M of stock across 20 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jun 17, 2026.
- The trade is 17.1% of the 116,842 shares held after it.
- 1 other insider sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President BURNETT JOSEPH sold about $387.6K of CLPT on Jun 29, 2026; 1 other insider sold within 30 days and 71 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Feb 25, 2026.
- The trade is 1.0% of the 191,388 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President BURNETT JOSEPH sold about $33.1K of CLPT on Jun 17, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Feb 25, 2026.
- The trade is 51.4% of the 116,842 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President BURNETT JOSEPH sold about $1.1M of CLPT on Jun 17, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 10, 2025.
- The trade is 6.2% of the 87,198 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Richards Timothy T. sold about $65.9K of CLPT on Jun 1, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 34.1% of the 46,935 shares held after it.
- 3 other insiders sold within 30 days.
- 71 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Klein Matthew B. sold about $185.4K of CLPT on May 21, 2026; 3 other insiders sold within 30 days and 71 funds added in the latest 13F quarter.20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.8M over 180 days
below 67% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
71 funds bought in last quarter
more than 54% of Medical Devices
Revenue
+17.8% year over year
more than 69% of Medical Devices
Margin
-69.1% net margin
below 75% of Medical Devices
Buybacks
no share repurchases reported
Short interest
17.6% of the float short (float per yahoo 2026-10-27) · 6.6 days to cover · settled 2026-10-15
more than 97% of Medical Devices
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 6 in the prior 90
Why it matters
The absence is the signal: 6 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch CLPT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-64.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CLPT: institutional holders (13F)
13F holdings, latest reported quarter
2,379,804 sh
$42.5M
2,375,861 sh
$42.4M
1,232,807 sh
$22.0M
816,547 sh
$14.6M
749,932 sh
$13.4M
Congress trades in CLPT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CLPT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JOSEPH BURNETT
Filed 2026-06-29
$369.6K
CLPT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Taylor Frigon Core Growth Fund
$408.8K position · as of 2026-05-31
1.1%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$1.6M position · as of 2026-06-30
1.1%
DWS Global Small Cap VIP
$409.0K position · as of 2026-06-30
0.5%
DWS Global Small Cap Fund
$889.6K position · as of 2026-07-31
0.4%
Dunham Small Cap Growth Fund
$341.9K position · as of 2026-07-31
0.4%
Invesco NASDAQ Future Gen 200 ETF
$77.5K position · as of 2026-05-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Burnett
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.8M
$2.1M
$1.2M
+62%
n/a
2024
$2.5M
$5.9M
$1.2M
+37%
n/a
2023
$2.0M
$1.5M
$884.7K
-57%
n/a
2022
$2.1M
$1.9M
$835.1K
-47%
n/a
2021
$1.5M
$986.4K
$592.5K
-29%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.8M sold by insiders over 180 days, 71 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CLPT financials
Revenue growth
+17.8%
XBRL, annual
Net margin
-69.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$42.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CLPT
| FY Dec 2025 | $37.0M |
| FY Dec 2024 | $31.4M |
| FY Dec 2023 | $24.0M |
| FY Dec 2022 | $20.6M |
| FY Dec 2021 | $16.3M |
| Jun 2026 | $10.9M |
| Mar 2026 | $12.1M |
| Dec 2025 | $10.4M |
| Sep 2025 | $8.9M |
| Jun 2025 | $9.2M |
| Mar 2025 | $8.5M |
| Dec 2024 | $7.8M |
| Sep 2024 | $8.1M |
At each fiscal year end
Single quarter
Net margin, TTM
-81.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CLPT
| FY Dec 2025 | -69.1% |
| FY Dec 2024 | -60.3% |
| FY Dec 2023 | -92.2% |
| FY Dec 2022 | -80.0% |
| FY Dec 2021 | -88.4% |
| Jun 2026 | -104.2% |
| Mar 2026 | -78.8% |
| Dec 2025 | -74.8% |
| Sep 2025 | -66.5% |
| Jun 2025 | -63.3% |
| Mar 2025 | -71.0% |
| Dec 2024 | -69.3% |
| Sep 2024 | -61.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$31.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CLPT
| FY Dec 2025 | -$24.4M |
| FY Dec 2024 | -$9.2M |
| FY Dec 2023 | -$14.4M |
| FY Dec 2022 | -$16.4M |
| FY Dec 2021 | -$12.9M |
| Jun 2026 | -$7.2M |
| Mar 2026 | -$8.6M |
| Dec 2025 | -$12.1M |
| Sep 2025 | -$3.3M |
| Jun 2025 | -$2.6M |
| Mar 2025 | -$6.4M |
| Dec 2024 | -$1.5M |
| Sep 2024 | -$1.2M |
At each fiscal year end
Single quarter
Debt to equity
4.66x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity CLPT
| FY Dec 2025 | 1.75x |
| FY Dec 2024 | 0.39x |
| FY Dec 2023 | 0.47x |
| FY Dec 2022 | 0.27x |
| FY Dec 2021 | 0.20x |
| Jun 2026 | 4.66x |
| Mar 2026 | 2.63x |
| Dec 2025 | 1.75x |
| Sep 2025 | 1.84x |
| Jun 2025 | 1.46x |
| Mar 2025 | 0.50x |
| Dec 2024 | 0.39x |
| Sep 2024 | 0.34x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.60x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt CLPT
| FY Dec 2025 | -0.49x |
| FY Dec 2024 | -0.90x |
| FY Dec 2023 | -1.38x |
| FY Dec 2022 | -1.63x |
| FY Dec 2021 | -1.29x |
| Jun 2026 | -0.60x |
| Mar 2026 | -0.52x |
| Dec 2025 | -0.49x |
| Sep 2025 | -0.45x |
| Jun 2025 | -0.39x |
| Mar 2025 | -1.13x |
| Dec 2024 | -0.90x |
| Sep 2024 | -0.89x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-226.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CLPT
| FY Dec 2025 | -95.6% |
| FY Dec 2024 | -81.2% |
| FY Dec 2023 | -76.1% |
| FY Dec 2022 | -38.4% |
| FY Dec 2021 | -56.3% |
| Jun 2026 | -226.5% |
| Mar 2026 | -149.7% |
| Dec 2025 | -95.6% |
| Sep 2025 | -103.1% |
| Jun 2025 | -85.7% |
| Mar 2025 | -76.2% |
| Dec 2024 | -81.2% |
| Sep 2024 | -68.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-46.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CLPT
| FY Dec 2025 | -37.3% |
| FY Dec 2024 | -46.2% |
| FY Dec 2023 | -45.0% |
| FY Dec 2022 | -27.1% |
| FY Dec 2021 | -30.3% |
| Jun 2026 | -46.2% |
| Mar 2026 | -47.1% |
| Dec 2025 | -37.3% |
| Sep 2025 | -46.0% |
| Jun 2025 | -38.5% |
| Mar 2025 | -49.7% |
| Dec 2024 | -46.2% |
| Sep 2024 | -43.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CLPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-47.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CLPT
| FY Dec 2025 | -41.7% |
| FY Dec 2024 | -61.6% |
| FY Dec 2023 | -53.5% |
| FY Dec 2022 | -29.8% |
| FY Dec 2021 | -30.7% |
| Jun 2026 | -47.1% |
| Mar 2026 | -49.4% |
| Dec 2025 | -41.7% |
| Sep 2025 | -53.6% |
| Jun 2025 | -49.6% |
| Mar 2025 | -70.3% |
| Dec 2024 | -61.6% |
| Sep 2024 | -53.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CLPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$296.6M
market value at close 2026-10-26 on 2026-07-27 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value CLPT
| FY Dec 2025 | $392.0M |
| FY Dec 2024 | $414.1M |
| FY Dec 2023 | $154.0M |
| FY Dec 2022 | $190.3M |
| FY Dec 2021 | $221.0M |
| Jun 2026 | $555.9M |
| Mar 2026 | $284.0M |
| Dec 2025 | $392.0M |
| Sep 2025 | $610.4M |
| Jun 2025 | $321.5M |
| Mar 2025 | $326.1M |
| Dec 2024 | $414.1M |
| Sep 2024 | $297.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-11.3%
TTM free cash flow over market value at close 2026-10-26
FCF yield CLPT
| FY Dec 2025 | -6.3% |
| FY Dec 2024 | -2.2% |
| FY Dec 2023 | -8.6% |
| FY Dec 2022 | -7.9% |
| FY Dec 2021 | -4.9% |
| Jun 2026 | -5.8% |
| Mar 2026 | -9.9% |
| Dec 2025 | -6.3% |
| Sep 2025 | -2.2% |
| Jun 2025 | -3.5% |
| Mar 2025 | -3.6% |
| Dec 2024 | -2.2% |
| Sep 2024 | -2.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CLPT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M |
| Gross profit | $22.7M | $19.1M | $13.6M | $13.5M |
| Operating income | -$24.2M | -$19.7M | -$22.4M | -$16.3M |
| Net income | -$25.5M | -$18.9M | -$22.1M | -$16.4M |
| EPS (diluted) | -0.90 | -0.70 | -0.90 | -0.68 |
| Operating cash flow | -$23.9M | -$8.9M | -$13.7M | -$16.2M |
| Cash | $45.9M | $20.1M | $23.1M | $27.6M |
| Long-term debt | $49.1M | n/a | $9.9M | $9.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
CLPT Stock Sonar score 6/7 axes
Find similar shapesCompareCLPT ranks highest on growth (69th percentile) and institutional and government (54th), and lowest on risk and compliance (7th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CLPT filings, in plain words
Are ClearPoint Neuro insiders buying or selling CLPT?
In the 180 days to 2026-10-28, ClearPoint Neuro insiders were net sellers, a net $1.8M across purchases and sales reported on Form 4, by 4 sellers.
Read the full summary
In the 180 days to 2026-10-28, ClearPoint Neuro insiders were net sellers of CLPT, a net $1.8M across purchases and sales reported on Form 4 by 4 sellers. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
